0.08
+6.67%
Close of 9 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Resverlogix
Its shares trade on Toronto Stock Exchange under the ticker RVX.TO. It has been listed since 12 October 2001.
Resverlogix Corp. engages in the research and development of pharmaceutical products for cardiovascular diseases. The company is headquartered in Calgary, Alberta. The company went IPO on 2001-10-12. The firm is developing apabetalone (RVX-208), a molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects for patients with high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, dialysis, Alzheimer's disease, Fabry disease, other orphan diseases, and peripheral artery disease. Apabetalone is being studied in a Phase III trial, BETonMACE, in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL).
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 12 Oct 2001
- Employees
- 28
- Website
- resverlogix.com ↗
Leadership
Pay as last reported
- Mr. Donald MccaffreyChairman of the Board, President, Chief Executive Officer, Secretary, since 2003C$565,200
- Mr. A. Brad CannChief Financial OfficerC$365,373
- Dr. Michael SweeneySenior Vice President - Clinical DevelopmentC$538,703
- Dr. Ewelina KulikowskiChief Scientific OfficerC$250,000
- Mr. Kelly McneillLead Independent Director, since 2006C$2,375
- Mr. Siu Lun ToIndependent DirectorC$2,375
- Mr. Kenneth ZuerblisIndependent DirectorC$2,375
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Resverlogix Corp benefits from a robust scientific foundation, backed by years of research and development in the field of epigenetics. This provides the company with a strong base for innovative drug discovery and development, enabling them to potentially address unmet medical needs.
- Resverlogix Corp has a promising drug pipeline with multiple compounds in different stages of development. This diversification reduces their dependency on a single product and increases the potential for revenue generation in the future. It also allows the company to target various therapeutic areas, expanding their market opportunity.
Weaknesses
- Resverlogix Corp heavily relies on the success of its clinical trials to demonstrate the safety and efficacy of its drug candidates. Delays or failures in clinical trials can significantly impact the company's progress and financial performance. The unpredictable nature of clinical trials poses a potential weakness for the company.
- Resverlogix Corp may face challenges due to limited financial resources for conducting extensive research and development activities. This can impact their ability to accelerate the development of their drug candidates or explore new opportunities. Seeking additional funding through partnerships or investments may be necessary to overcome this weakness.
Opportunities
- Resverlogix Corp has the opportunity to expand its market presence by targeting emerging markets and therapeutic areas with unmet medical needs. By identifying and addressing these untapped markets, the company can diversify its revenue streams and potentially achieve substantial growth.
- Resverlogix Corp can explore strategic partnerships and collaborations with pharmaceutical companies, research institutions, or academic organizations. Such partnerships can provide access to additional resources, expertise, and market leverage, accelerating the development and commercialization of their drug candidates.
Threats
- Resverlogix Corp operates in a highly regulated industry where regulatory approval is imperative for market entry. Delays, rejections, or stringent regulations from health authorities can pose significant threats to the company's ability to bring their drug candidates to market and generate revenues.
- Resverlogix Corp faces intense competition from other pharmaceutical companies, both established players and emerging biotech firms. The presence of strong competitors with similar drug candidates or innovative solutions can limit market share and create challenges for product differentiation and commercial success.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.